Check our new preprint defining a novel cell engineering approach to generate "physically optimized" T cells that move better through complex solid tumor environments to better encounter and kill carcinoma cells!
biorxiv.org/content/10.64898…@theNCI@AmericanCancer#CCBIR#CMITIE
Today marks 9 years since the enormous loss of our dear friend & colleague Patti @patricia_keely to #PancreaticCancer
The ECM giant who gave us the tumor-associated collagens - TACs signatures
She would have loved to see the @RevMedicines success in launching Ras inhibitors
💜
We are very excited to share our newest results, published in Science Advances: “Compressive stress-driven Piezo1 activation and Rho-ROCK mechanotransduction promote tumor progression via epigenetic mechanical memory”. doi.org/10.1126/sciadv.aeb12…
New in @ScienceMagazine: Endeavor Award team members @SageJulien and K. Christopher Garcia have engineered "trikines"—synthetic cytokines that mix & match receptor signals to rewire immune cells.
The result? Better tumor control & far less toxicity.
science.org/doi/10.1126/scie…
An update to the Hallmarks of Cancer framework for understanding (and researching) what causes human cancers. spkl.io/6010Aqwbi
Douglas Hanahan
@CellCellPress
Researchers harness lipid nanoparticles and mRNA to generate CAR T cells in vivo to target hepatic stellate cells that drive liver #fibrosis in MASH, and show this strategy can dampen fibrosis and inflammation in mice. @ScienceTMscim.ag/3LW0KXQ
We’re excited to announce that Anirban Maitra, MD (@Aiims1742)—a pre-eminent physician-scientist whose work has widely influenced the field of pancreatic cancer research—has been appointed the new director of @Perlmutter_CC here at NYU Langone.
For more: bit.ly/4t2xDD2
Pancreatic ductal adenocarcinoma needs better RAS inhibitors.
But that alone will not be enough.
In this preclinical study KRAS blockade predictably activates EGFR and STAT3. As long as one escape route remains open, pancreatic tumors persist.
Upfront triple inhibition of RAS (daraxonrasib), EGFR (afatinib) and STAT3 (SD36) achieved complete and durable tumor regression with no relapse beyond 200 days
The signal is strong, but the message is clear:
even if RASolute-302 (phase 3) 🔜is positive, RAS monotherapy will not be sufficient, especially in metastatic PDAC. Progress in RAS driven cancer depends on controlling resistance safely.
pnas.org/doi/10.1073/pnas.25…@OncoAlert
We're looking for a Research Assistant / Senior Research Assistant to join our team. If you're interested in studying the extracellular matrix and tumour microenvironment in cancer, then get in touch. Applications will be reviewed on a rolling basis.
garvan.wd3.myworkdayjobs.com…
Just in case any one is wondering: Biomedical scientists spend an average of 12 years in training before reaching an independent position. That is more than most medical residences.
🚨 Exciting Opportunity Alert! 🚨
Are you passionate about understanding why cancer patients relapse and uncovering the secrets of tumor dormancy and metastasis?
Join our dynamic lab @templemedschool and @FoxChaseCancer
✨ Please RT to spread the word! ✨